Compare ESPR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | IVA |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.5M | 804.2M |
| IPO Year | 2013 | 2020 |
| Metric | ESPR | IVA |
|---|---|---|
| Price | $3.09 | $6.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $6.67 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 5.6M | 414.1K |
| Earning Date | 03-03-2026 | 09-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $303,802,000.00 | $19,929,536.00 |
| Revenue This Year | $26.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $0.69 | $2.11 |
| 52 Week High | $4.18 | $7.98 |
| Indicator | ESPR | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 32.93 | 78.22 |
| Support Level | $3.00 | $4.48 |
| Resistance Level | $4.18 | $5.17 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | -0.11 | 0.19 |
| Stochastic Oscillator | 4.26 | 94.28 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.